![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
could someone help me please, I don't understand why Skye is not supported? XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
US Stock MarketDetailed Quotes
SKYE SKYE BIOSCIENCE INC
- 3.160
- +0.100+3.27%
Close Feb 14 16:00 ET
- 3.160
- 0.0000.00%
Post 20:01 ET
95.87MMarket Cap5.96P/E (TTM)
3.300High3.020Low98.25KVolume3.070Open3.060Pre Close307.75KTurnover0.74%Turnover RatioLossP/E (Static)30.34MShares19.41052wk High1.26P/B42.19MFloat Cap2.31052wk Low--Dividend TTM13.35MShs Float64.725Historical High--Div YieldTTM9.15%Amplitude1.440Historical Low3.132Avg Price1Lot Size
SKYE BIOSCIENCE INC Stock Forum
Sign in to post a comment
$Veru Inc (VERU.US)$ $Sacks Parente Golf (SPGC.US)$ $TuHURA Biosciences (HURA.US)$ $Reborn Coffee (REBN.US)$ $Siyata Mobile (SYTA.US)$ $SKYE BIOSCIENCE INC (SKYE.US)$ $Envirotech Vehicles (EVTV.US)$ $Nextracker (NXT.US)$ $Ranpak Holdings (PACK.US)$ $Lucas GC (LGCL.US)$ $60 Degrees Pharmaceuticals (SXTP.US)$ $Banzai International (BNZI.US)$ $Silexion Therapeutics (SLXN.US)$ $Signing Day Sports (SGN.US)$ $36KR Holdings (KRKR.US)$
📊⚡️📊
📊⚡️📊
6
1
$SKYE BIOSCIENCE INC (SKYE.US)$ Reuters· 1 min ago
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
$SKYE BIOSCIENCE INC (SKYE.US)$
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
Skye Bioscience (Nasdaq: SKYE) has commented on Novo Nordisk's Phase 2a top-line data for monlunabant, a small-molecule oral CB1 inverse agonist. The study met its primary endpoint, showing at least 6% placebo-adjusted weight loss at 16 weeks. However, dose-dependent neuropsychiatric side effects were observed.
Skye highlights the advan...
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
Skye Bioscience (Nasdaq: SKYE) has commented on Novo Nordisk's Phase 2a top-line data for monlunabant, a small-molecule oral CB1 inverse agonist. The study met its primary endpoint, showing at least 6% placebo-adjusted weight loss at 16 weeks. However, dose-dependent neuropsychiatric side effects were observed.
Skye highlights the advan...
1
$SKYE BIOSCIENCE INC (SKYE.US)$
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity. Skye Bioscience (Nasdaq: SKYE) has launched a Phase 2 clinical trial, CBeyond™, to evaluate its peripheral CB1 inhibitor, nimacimab, for weight loss in patients with obesity.
The study will assess nimacimab's efficacy as a monotherapy and in combination with a GLP-1 receptor agonist (Wegovy®). Key aspects of the trial include:
- 12...
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity. Skye Bioscience (Nasdaq: SKYE) has launched a Phase 2 clinical trial, CBeyond™, to evaluate its peripheral CB1 inhibitor, nimacimab, for weight loss in patients with obesity.
The study will assess nimacimab's efficacy as a monotherapy and in combination with a GLP-1 receptor agonist (Wegovy®). Key aspects of the trial include:
- 12...
$Scorpius Holdings (SCPX.US)$ Look at their peers. This is really undervalued. Once in a lifetime opporturnity.
$SKYE BIOSCIENCE INC (SKYE.US)$ $Boundless Bio (BOLD.US)$
$SKYE BIOSCIENCE INC (SKYE.US)$ $Boundless Bio (BOLD.US)$
1
$SKYE BIOSCIENCE INC (SKYE.US)$
![]()
this just shows it pays to follow up on things..
I had been eyeing this off for a while. Tried to buy in Jan at 0.019-0.020 but then left it alone as for whatever reason I wasn't able to buy.
Now I see it's gone from 0.02000 to a whopping 3.15.
Damn you Mr Market, that's ice cold!
I had been eyeing this off for a while. Tried to buy in Jan at 0.019-0.020 but then left it alone as for whatever reason I wasn't able to buy.
Now I see it's gone from 0.02000 to a whopping 3.15.
Damn you Mr Market, that's ice cold!
3
cannot believe I tried to buy this at 0.020 a few months ago but said 'stock not supported' .... makes me happy to have been right and furious to not have the cold hard cash on it now $SKYE BIOSCIENCE INC (SKYE.US)$
5
No comment yet
Trending Stocks
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
MooMamaLlama OP : analyst prices of 18+ is such a massive leap,leads me to believe its longer term and/or speculation...
however, Morningstar puts Fair Value at 12, and I'm more inclined to believe they put more effort into coming to their conclusions
it jumped a lovely 9%+ last night and another 2.8%+ in Post market this morning